Cetuximab and panitumumab, therapeutic monoclonal antibodies (mAb) against epidermal growth factor receptor (HER1/EGFR), are frequently used, but are less effective in a subset of cancers with KRAS mutations.6 In clinical trials in patients with KRAS‐mutated CRC, multiple combination therapies such as AKT inhibitor‐MEK inhibitor,7 MEK inhibitor‐FOLFIRI,8 and cetuximab‐FOLFOX9 have shown disappointing results. Here, MAP2K7 is linked to cancer.